Steve Davis, Acadia Pharmaceuticals CEO

Up­dat­ed: Aca­dia wins first FDA ap­proval for Rett syn­drome drug

The FDA on Fri­day ap­proved Aca­dia Phar­ma­ceu­ti­cals’ treat­ment for Rett syn­drome, a rare neu­rode­vel­op­men­tal dis­or­der, which will be sold un­der the brand name Day­bue (trofine­tide), the com­pa­ny an­nounced.

The av­er­age list price for the drug will be about $575,000 to $595,000 a year, CEO Steve Davis said on a con­fer­ence call Mon­day morn­ing. That comes from a $21.10 per mil­li­liter price that’s used for weight-based dos­ing. The com­pa­ny’s “net re­al­ized cost” will be ap­prox­i­mate­ly $375,000, he said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.